Dignify Therapeutics was awarded a $159,000  phase I Small Business Innovation Research (SBIR) grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health (NIH).  

Dignify is focused on restoring bladder and bowel control to people with spinal injury, spina bifida, and other neurological conditions with the aim of improving the quality-of-life for individuals that rely on bladder catheters and bowel programs for voiding. 

“These funds will support the ongoing development of our lead product candidate, DTI-100, through the IND approval process and into clinical trials,” said Karl Thor, president and CSO.  “This SBIR award, together with future non-dilutive funding, will augment the Company’s current efforts to raise up to $3 million from private investors to develop DTI-100 through Phase II clinical trials.”   

Previous articleAvastin Wins FDA Nod for Advanced Forms of Cervical Cancer
Next articleAlmac Adding 348 Jobs at Northern Ireland HQ